This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Pivotal Trial Results
Post-Hoc Analysis Results
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
Example of description text sitting alongside header
JADE EXTEND
Study Design
EASl-75
IGA 0/1
JADE EXTEND is an ongoing, phase 3, long-term extension safety study for eligible subjects receiving CIBINQO who have completed a qualifying JADE parent study. The primary endpoints in JADE EXTEND are the incidence of safety events and clinical abnormalities.1 See the JADE EXTEND study design.
JADE EXTEND is an ongoing, phase 3, long-term extension safety study for eligible subjects receiving CIBINQO who have completed a qualifying JADE parent study. The primary endpoints in JADE EXTEND are the incidence of safety events and clinical abnormalities.1 See the JADE EXTEND study design.
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
JADE EXTEND is an ongoing, phase 3, long-term extension safety study for eligible subjects receiving CIBINQO who have completed a qualifying JADE parent study. The primary endpoints in JADE EXTEND are the incidence of safety events and clinical abnormalities.1 See the JADE EXTEND study design.
RECOMMENDED DOSE: CIBINQO 100 mg
If response to 100 mg is inadequate, consider increasing to 200 mg. Discontinue if inadequate response is seen after dose increase.
Resources such as the discussion guide and patient brochure can help
A product representative is available to help you learn more about CIBINQO
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426
This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
© 2024 Pfizer Inc. All rights reserved.